Division of Medical Microbiology, Department of Pathology and Laboratory Medicine, Vancouver Coastal Health, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Diagn Microbiol Infect Dis. 2023 Apr;105(4):115832. doi: 10.1016/j.diagmicrobio.2022.115832. Epub 2022 Oct 13.
We compared the performance of ID NOW™ COVID-19 assay nasal swabs with RT-PCR of nasopharyngeal swabs for SARS-CoV-2 in an outbreak setting, determining whether addition of RT-PCR of residual nasal swabs (rNS) (post ID NOW™ elution) would increase overall analytic sensitivity. Devices were placed at 2 long term and 1 acute care sites and 51 participants were recruited. Prospective paired nasopharyngeal and nasal samples were collected for RT-PCR and ID NOW™. ID NOW™ had a positive and negative categorical agreement of 86% and 93% compared to RT-PCR of nasopharyngeal swabs. Sensitivity and specificity of the ID NOW™ was 86% and 100%, positive and negative predictive value was 100% and 95% (COVID-19 positivity rate: 8%). Addition of rNS RT-PCR increased the positive and negative categorical agreement to 93% and 97%. Based on these results, we propose an alternative workflow which includes complementary testing of rNS on a secondary assay.
我们在疫情爆发期间将 ID NOW™ COVID-19 检测鼻咽拭子与 RT-PCR 检测比较，以确定是否增加对 ID NOW™洗脱后剩余鼻咽拭子（rNS）的 RT-PCR 检测可提高整体分析灵敏度。设备放置在 2 个长期和 1 个急性护理地点，招募了 51 名参与者。前瞻性采集配对的鼻咽和鼻腔样本，进行 RT-PCR 和 ID NOW™检测。与 RT-PCR 检测鼻咽拭子相比，ID NOW™ 的阳性和阴性分类一致性分别为 86%和 93%。ID NOW™ 的敏感性和特异性分别为 86%和 100%，阳性和阴性预测值分别为 100%和 95%（COVID-19 阳性率：8%）。增加 rNS RT-PCR 检测可将阳性和阴性分类一致性提高到 93%和 97%。基于这些结果，我们提出了一种替代工作流程，包括在辅助检测上互补检测 rNS。
